Articles related to CONTROLLED MEDICINES

Primary care physicians increasingly inherit adult ADHD stimulant prescriptions amid specialist shortages and medication supply disruptions. Expert guidance highlights diagnostic verification, monitoring, and risk-assessment considerations without establishing a single standardized approach.

A psychiatric mental health NP outlined clinical and regulatory safeguards for virtual ADHD stimulant prescribing, noting that federal telehealth flexibilities extending through December 2026 do not supersede stricter state-level requirements.

A clinician educator outlines a framework for managing perceived “entitled” or demanding patient encounters by reframing behavior, applying motivational interviewing, and using perspective-based denial when setting limits.

Viatris recalled one lot of Xanax XR 3-mg extended-release tablets after failed dissolution testing, with the FDA classifying the action as Class II and reporting no adverse events to date.

Rather than referring patients with substance use disorder to treatment, the doctor prescribed an “astronomical amount of drugs” in dangerous combinations of addictive drugs to those patients.

Understanding the distinction between probable cause for arrest and evidence required for conviction is crucial for prescribers managing controlled substances.